Latest Business Development News

FirstWave Cloud Technology delivered a strong Q3 FY26 with a $1.40m net operating cash inflow and a major two-year licensing agreement with Mexico’s Banobras bank, marking a key milestone in its AI compliance pivot.

Dalaroo Metals completed full acquisition of its Greenland Blue Lagoon Project, confirming a district-scale critical minerals system, while advancing high-grade gold exploration in Côte d’Ivoire with drill-ready targets and expanding investor access via a US OTCQB listing.

RareX Limited has advanced its rare earths ambitions by securing a key mining lease at Cummins Range, appointing a strategic board member, and raising $5 million to fund exploration and development.

Eden Innovations has expanded its EdenCrete Pz7 installations across North America, launched a new defence-focused division EdenShield, and eliminated costly debt, positioning for growth with a $4 million capital raise.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.

Estrella Resources has initiated Timor-Leste’s inaugural hard rock mineral extraction at its Ira Miri manganese project, advancing towards full-scale mining and simultaneously progressing a major limestone resource at Werumata.

Battery Age Minerals delivered maiden drilling success at Austria’s Bleiberg project, expanded its Apex Germanium-Gallium footprint in Utah by 40%, and confirmed high-grade gold-silver mineralisation at Argentina’s El Aguila. The company also progressed germanium technology evaluations and appointed a new CEO.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

Orbital Corporation advances its UAV engine production and hybrid propulsion technology while managing a $0.5 million net cash outflow in Q1 2026, supported by a $43 million business pipeline and new international contracts.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Volt Resources has secured a major extension and volume increase to its Bunyu graphite offtake agreement while progressing high purity graphite production and downstream refinery development in the US.